FLEx: Inducible Point Mutation
FLEx technology allows scientists to induce the expression of a mutated gene or a reporter gene at an appropriate time during the lifetime of the animal model.
FLEx technology was developed and validated by Prof. Chambon and Dr. Ghyselinck at the Institut de Génétique et de Biologie, Moléculaire et Cellulaire (France).
Access to time- and tissue-restricted point mutant models.
This technique has become the gold standard for the generation of kinase-dead mutants and for the generation of functional KO mice. The mutant gene is induced in a temporal- and tissue-specific manner. Mutant gene expression is physiologically relevant and appropriate since the gene continues to be expressed from its endogenous locus.
- The FLEx model bypasses potentially lethal phenotypes associated with the expression of the mutation.
- The FLEx model allows the researcher to analyze the effect of the mutated gene when the mouse is an adult.
- With FLEx mice scientists can reproduce a particular pathology that is triggered by a mutation and that normally manifests in adulthood.
- The FLEx mutation is expressed from the endogenous locus and can therefore be regulated physiologically.
Access to monitoring of tissue-specific and temporally-specific gene ablation.
FLEx technology can also create conditional mouse models for the express purpose of monitoring gene deletion.
This approach is often valuable when:
- No reliable antibody exists that can detect your target gene or quantify its deletion.
- The customer is interested in monitoring the trafficking of gene-deleted cells.
- The customer is interested in monitoring gene expression patterns.
References describing applications using FLEx technology:
Inducible Knock-out: F. Schnütgen et al. Nature Biotech 2003. A directional strategy for monitoring Cre-mediated recombination at the cellular level in the mouse.
Gene trapping: F. Schnütgen et al. PNAS 2005. Genomewide production of multipurpose alleles for the functional analysis of the mouse genome.
Gene reporter switch: D. Atasoy et al. J Neuroscience 2008. A FLEX switch targets Channelrhodopsin-2 to multiple cell types for imaging and long-range circuit mapping.
genOway licenses secure your discoveries and research.
genOway holds an exclusive license from the University of Strasbourg, Inserm and CNRS, France. Patents for this technology are issued and maintained in US (US7074611) and in Europe (EP1383891).
The customer will have a permanent, non-exclusive and royalty-free license for the patented and/or proprietary technologies employed to create the rodent model. This guarantees the customer full rights to use such a model for any and all R&D purposes.
The customer also retains ownership of the deliverables and can patent the model developed. genOway will have no claim on the results generated using the model we provide for you.